References
- McCrone P, Dhanasiri S, Patel A, et al. Paying the price: the cost of mental health care in England to 2026. London: King’s Fund, 2008
- Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92
- Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183:514-9
- Anderson I, Pilling S, Barnes A, et al. Depression: the treatment and management of depression in adults. National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence, 2009. United Kingdom
- Cowen PJ, Ogilvie AD, Gama J. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Curr Med Res Opin 2005;21:345-56
- Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006;188:346-53
- Kelin K, Berk M, Spann M, et al. Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study. Int J Clin Pract 2010;64(6):719-26
- Perahia DG, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-16
- Hudson JI, Perahia DG, Gilaberte I, et al. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 2007;7:43
- Sheehan DV, Keene MS, Eaddy M, et al. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 2008;22:963-73
- Wade AG, Fernandez JL, Francois C, et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconomics 2008;26:969-81
- Benedict A, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord 2010;120:94-104
- Shi L, Liu J, Campbell C, et al. Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study. Curr Med Res Opin 2010;26(12):2715-21
- Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004;65:521-30
- Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008;20:187-93
- Kutner M, Nachtsheim C, Neter J. Applied Linear Regression Models. 4th edn. McGraw–Hill Irwin, 2004. United States
- Leuchter AF, Husain MM, Cook IA, et al. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med 2010;40:239-51
- Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
- Tesfaye S. Advances in the management of diabetic peripheral neuropathy. Curr Opin Support Palliat Care 2009;3:136-43
- Zakrzewska JM. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother 2010;11:1239-54
- Rao SG. Current progress in the pharmacological therapy of fibromyalgia. Expert Opin Investig Drugs 2009;18:1479-93
- Marcus DA. Fibromyalgia: diagnosis and treatment options. Gend Med 2009;6(2 Suppl):139-51